Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GT1708F is a highly active and specific inhibitor of SMO protein, which inhibits the activity of SMO protein to affect the activity of the Hedgehog pathway and the expression of its downstream related proteins, thereby treating IPF.
Lead Product(s): GT1708F
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GT1708F
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
GT20029, a proteolysis targeting chimera (PROTAC) compound, is a topical AR degrader causing shrinkage and miniaturization of hair follicles caused by the activation of AR signaling pathway. It is being developed for acne vulgaris and androgenetic alopecia.
Lead Product(s): GT20029
Therapeutic Area: Dermatology Product Name: GT20029
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
GT20029, a proteolysis targeting chimera (PROTAC) compound, is a topical AR degrader causing shrinkage and miniaturization of hair follicles caused by the activation of AR signaling pathway. It is being developed for acne vulgaris and androgenetic alopecia.
Lead Product(s): GT20029
Therapeutic Area: Dermatology Product Name: GT20029
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
GT19715 demonstrated anti-leukemia efficacy in patient-derived AML cells with TP53 mutations, especially in immature CD34+ fractions; and treatment of GT19715 in mice eradicated lymphoma and leukemia cells in Daudi Burkitt’s lymphoma and Venetoclax-resistant AML models.
Lead Product(s): GT19715
Therapeutic Area: Oncology Product Name: GT19715
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
GT20029 is a topical androgen receptor (AR) degrader using Kintor Pharma's PROTAC platform. GT20029 can effectively block the shrinkage and miniaturization of hair follicles caused by activated AR signaling pathway.
Lead Product(s): GT20029
Therapeutic Area: Dermatology Product Name: GT20029
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
KX-826 (pyrilutamide) is an AR antagonist and a potential first-in-class topical drug for treatment of androgenetic alopecia and acne vulgaris continues to demonstrate good efficacy and safety in phase II clinical trial to benefit more people suffering from acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2022
Details:
KX-826 (pruxelutamide) effectively reduced hospitalization/mortality; in particular, for subjects who completed the medication for more than 7 days and middle-and-high-age COVID-19 patients with high risk factors, the protection rate was 100%.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: IQVIA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022